CLINICAL TRIAL
Treatment for Diabetes Mellitus, Type 2
EnrollingByInvitation · 18+ · All Sexes · Boston, MA
A Cognitive Behavioral Digital Therapeutic InterventiON for Glycemic Control in Type 2 Diabetes Mellitus
See full descriptionAbout the trial for Diabetes Mellitus, Type 2
Eligible Conditions
Diabetes Mellitus, Type 2 · Diabetes Mellitus · Diabetes Type 2
Treatment Groups
This trial involves a single treatment. Treatment is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.
BT-001
DEVICE
Eligibility
This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.
Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:View All
Current (within 3 months prior to enrollment) HbA1c >=7.01%
Possession of and ability to use Android or iPhone mobile phone
Speaks and reads in English
Willing to measure frequent fasting finger glucose measurements as part of the App utilization
Odds of EligibilitySimilar Trials
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Approximate Timelines
Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Baseline and day 180, 365
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like
Measurement Requirements
This trial is evaluating whether Treatment will improve 2 secondary outcomes in patients with Diabetes Mellitus, Type 2. Measurement will happen over the course of Baseline and Day 365.
Significant change in HbA1c
BASELINE AND DAY 365
Proportion of patients with a ≥ 0.4% decrease in HbA1c at 12 months within each study groupChange in HbA1c
BASELINE AND DAY 180, 365
Change in HbA1c from baseline (enrollment) and from 6 months, to 12 months after enrollment between groupsPatient Q & A Section
Ask a question about the study
Other questions from users
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any geographic restrictions to consider when applying for this trial?
Patients from any state can participate in this trial, so long as they are able to attend all treatment sessions.
Will my insurance cover participating in this trial?
In order to understand how insurance coverage works for this trial, you will need to contact the study coordinator.
See if you qualify for this trial
Get access to this novel treatment for Diabetes Mellitus, Type 2 by sharing your contact details with the study coordinator.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Power